Skip to main content

Vanguard Group Inc

SEC CIK
0000102909
Latest filing
Jan 29, 2026

SRNE holding history

Sorrento Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

SRNE overviewAll 13F holders of SRNEFull Q4 2025 holdings

Shares (Q1 2023)
0
Sold out in Q1 2023
Value
$0
% of portfolio
0.0%
Quarters held
8
Since Q1 2021
Holdings of SRNE by Vanguard Group Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20230$00.0%−29,535,954−100.0%Sold outHolders
Q4 202229,535,954$26.2M<0.1%+7,019,380+31.2%AddedHolders
Q3 202222,516,574$35.4M<0.1%+1,620,150+7.8%AddedHolders
Q2 202220,896,424$42.0M<0.1%+4,995,039+31.4%AddedHolders
Q1 202215,901,385$37.1M<0.1%+208,655+1.3%AddedHolders
Q4 202115,692,730$73.0M<0.1%+186,237+1.2%AddedHolders
Q3 202115,506,493$118.3M<0.1%+1,376,502+9.7%AddedHolders
Q2 202114,129,991$136.9M<0.1%+575,472+4.2%AddedHolders
Q1 202113,554,519$112.1M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.